Cyclogenix Enters Research Collaboration with Wyeth Pharmaceuticals (New Jersey) (WYE) and Queensland’s IMBcom  
2/26/2009 11:44:54 AM

ABERDEEN, Scotland--(BUSINESS WIRE)--Cyclogenix Ltd today announced that it has entered into license and research agreements with Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE) and IMBcom, The University of Queensland’s (UQ) company for commercializing technology from the Institute for Molecular Bioscience (IMB).